Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apremilast versus etanercept versus placebo in adults with moderate to severe plaque psoriasis
2012-000859-14Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Aug 2012
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in plaque psoriasis and psoriasis comparing Apremilast arm, Etanercept arm and Placebo arm (3 arms). Primary endpoint: PASI-75 response for apremilast versus placebo at Week 16. Started Aug 2012; status: completed.
02
Drugs
apremilastetanercept
03
Conditions
plaque psoriasispsoriasis
Beyond the preview
Go deeper on 2012-000859-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000859-14.